Cortechs.ai | Volumetric Post-Processing Becoming Standard MRI Procedure

Volumetric Post-Processing Becoming Standard MRI Procedure

Cortechs.ai offers the most advanced artificial-intelligence-based methods for MRI post-processing and delivers accurate and clinically relevant quantitative data used in the diagnosis of neurodegenerative diseases.

Chief Executive Officer, Chris Airriess, PhD, discusses the value of volumetric post-processing with Suzie Bash, MD of RadNet San Fernando Valley.

Dr. Airriess: Increasingly we’re seeing hospitals and imaging centers making volumetric post-processing a standard procedure. Why do you think they’re making this decision?

Dr. Bash: I think it’s a decision that is really driven by recognized value. In my experience, once a referring physician orders volumetric post-processing for a particular clinical scenario, they immediately see the true value in the report and the impact that information has on patient management. This then drives their desire to receive volumetric post-processing on all future exams.

Dr. Airriess: What are the benefits of processing all head MRIs through products like NeuroQuant, LesionQuant, or PETQuant?

Dr. Bash: One of the greatest benefits of volumetric imaging is the elimination of subjectivity. So estimates of volume have always been incorporated into standard MRI brain reports. The radiologist traditionally always comments on the presence and degree of atrophy on each frame they evaluate. Additionally, if a patient has multiple sclerosis, the neuroradiologist always estimates the volume of plaque burden, which is characterized as mild, moderate, or severe. We want our referring physicians to be able to read our MRI reports and in doing so be able to visualize the anatomy of their patient’s brains. The problem is, we all have different sensitivities in characterizing volume, so what I might consider moderate cerebral atrophy, my colleague might consider severe.

Quantitative volumetric imaging eliminates reader subjectivity. It tells us exactly what degree of atrophy is statistically significant for patient age, and it calculates the true volume of plaque burden in patients that have MS. That information adds tremendous value. It makes us better clinicians. It also makes the referring physicians better providers since it can impact clinical management. And ultimately, it directly benefits the patient by aiding in diagnosis and accurately assessing for the true progression of the disease over time.

Dr. Airriess: Do you think this type of use will become more common?

Dr. Bash: Yes. I think the trend towards obtaining volumetric post-processing will increase over time. Really the only force against it is the lack of awareness that this technology exists. Once a referring physician knows that it’s possible to add value in a particular clinical scenario, there’s really no desire to go back to not using this technology every subsequent time. There is really no downside, particularly as the one to two required sequences for volumetric imaging are now fairly routine sequences on all higher-end magnets, so there’s essentially no time cost in exam length for volumetric data acquisition.

For more videos on Cortechs.ai volumetric imaging solutions, visit our youtube channel.

More Resources

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

02/19/2026

How Cortechs.ai Protects ePHI: HIPAA‑Aligned Controls—and Beyond

Cortechs.ai’s HIPAA-aligned, defense-in-depth security safeguards ePHI across AI workflows—exceeding baseline compliance standards.

02/11/2026

NeuroQuant Normative Database: Advancing Age‑ and Sex‑Specific Brain Volumetry

Learn how the latest updates to the NeuroQuant normative database white paper strengthen age- and sex-specific brain volumetry and enhance clinical confidence.

02/06/2026

NeuroQuant Normative Database: A Standard for Age- and Sex-Specific Brain Volumetry

Whitepaper: How Cortechs.ai’s normative database was created to accurately compare an individual’s brain structure volume to a healthy population.
Scroll to Top